English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA trial emulation study of veterans with COVID-19 found that the use of the antiviral nirmatrelvir–ritonavir was not effective for reducing the risk for many post-COVID-19 conditions, including cardiac, pulmonary, renal, gastrointestinal, neurologic, mental health, musculoskeletal, or endocrine symptoms. Nirmatrelvir–ritonavir was associated only with a reduced risk for combined thromboembolic events. The study is published in Annals of Internal Medicine.
Tag: ritonavir
Nirmatrelvir plus ritonavir may reduce risk for hospitalization or death from COVID-19
A retrospective cohort study of more than 44,000 nonhospitalized persons diagnosed with COVID-19 found that nirmatrelvir plus ritonavir reduced the overall risk of hospitalization and death. The study is published in Annals of Internal Medicine.
Study Shows Paxlovid Can Safely Be Used to Reduce Risk of Severe COVID in People Who Are Pregnant
Findings from a Johns Hopkins Medicine research study published today in JAMA Network Open provide strong evidence that people who are pregnant and have been infected with SARS-CoV-2 (the virus that causes COVID-19) can safely take the antiviral drug Paxlovid to reduce the possibility of severe disease.
New Oral Antiviral Drug Reduces Death in Early COVID-19
Researchers note that health care providers are now able to add to their armamentarium against COVID-19 their prescription of this new antiviral drug for high-risk, newly-infected patients as soon as possible following diagnosis or within five days of the onset of symptoms.